96136-13-9Relevant academic research and scientific papers
Enantioselective Organocatalyzed Consecutive Synthesis of Alkyl 4,5-Dihydrofuran-2-carboxylates from α-Keto Esters and (Z)-β-Chloro-β-nitrostyrenes
Becerra, Diana,Raimondi, Wilfried,Dauzonne, Daniel,Constantieux, Thierry,Bonne, Damien,Rodriguez, Jean
supporting information, p. 195 - 201 (2016/12/24)
Alkyl 4,5-dihydrofuran-2-carboxylates can be efficiently obtained via an enantioselective organocatalyzed consecutive reaction between α-keto esters and (Z)-(2-chloro-2-nitroethenyl)benzenes. The overall sequence combines a (R,R)-TUC-catalyzed Michael addition with a DABCO-promoted intramolecular O-alkylation leading to the title products as single diastereomers with enantiomeric excesses from 86% up to 97%.
Activation of 1,2-keto esters with Takemoto's catalyst toward michael addition to nitroalkenes
Raimondi, Wilfried,Basle, Olivier,Constantieux, Thierry,Bonne, Damien,Rodriguez, Jean
supporting information; experimental part, p. 563 - 568 (2012/04/17)
When activated with Takemoto's catalyst, 1,2-keto esters constitute versatile nucleophiles in the Michael addition reaction with nitroalkenes affording synthetically valuable, optically active anti-adducts in very good yields and high enantiomeric excesses. Copyright
Amino acid derivatives inhibiting extracellular matrix metalloproteinase and TNF alpha release
-
Page column 38, (2010/11/29)
The invention concerns compounds of general formula (X) in which Y represents in particular —CONHOH, R1represents in particular a C1-C5alkyl group, AA represents an amino acid, or an amino acid sequence, and R3represents in particular a group of formula —NH—(CH2)2—SCH3. The invention also concerns the pharmaceutical compositions containing them, and the methods for obtaining them.
INHIBITORS OF TNF-ALPHA SECRETION
-
, (2008/06/13)
Compounds and methods are disclosed that are useful in inhibiting the TNF-α converting enzyme (TACE) responsible for cleavage of TNF-. alpha. precursor to provide biologically active TNF-α. The compounds employed in the invention are peptidyl derivatives having active groups capable of inhibiting TACE such as, hydroxamates, thiols, phosphoryls and carboxyls.
